Investment Analysts’ Weekly Ratings Changes for Adherex Technologies (FENC)

Adherex Technologies (NASDAQ: FENC) recently received a number of ratings updates from brokerages and research firms:

  • 11/18/2026 – Adherex Technologies had its price target raised by HC Wainwright from $16.00 to $17.00. They now have a “buy” rating on the stock.
  • 11/16/2026 – Adherex Technologies had its “buy” rating reaffirmed by B. Riley Financial. They now have a $19.00 price target on the stock, up from $18.00.
  • 11/13/2026 – Adherex Technologies was upgraded by Weiss Ratings from “sell (d-)” to “hold (c-)”.
  • 11/12/2026 – Adherex Technologies was upgraded by Zacks Research from “hold” to “strong-buy”.
  • 10/15/2026 – Adherex Technologies had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Adherex Technologies Trading Down 2.8%

FENC stock traded down $0.38 during mid-day trading on Friday, hitting $13.07. The stock had a trading volume of 267,508 shares, compared to its average volume of 209,940. The firm has a fifty day simple moving average of $10.75 and a 200 day simple moving average of $9.47. The firm has a market capitalization of $460.37 million, a P/E ratio of 1,307.30 and a beta of 1.29. Adherex Technologies Inc. has a 52 week low of $5.65 and a 52 week high of $13.85.

Adherex Technologies (NASDAQ:FENC – Get Free Report) last announced its quarterly earnings data on Thursday, November 12th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.02. Adherex Technologies had a net margin of 2.52% and a return on equity of 8.96%. The business had revenue of $19.61 million for the quarter, compared to analysts’ expectations of $18.87 million. As a group, equities analysts expect that Adherex Technologies Inc. will post 0.32 earnings per share for the current fiscal year.

Insider Buying and Selling at Adherex Technologies

In other news, CFO Robert Andrade sold 75,000 shares of the business’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $11.78, for a total transaction of $883,500.00. Following the completion of the transaction, the chief financial officer owned 217,675 shares of the company’s stock, valued at approximately $2,564,211.50. The trade was a 25.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pierre Sargis Sayad sold 12,000 shares of the company’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $12.18, for a total value of $146,160.00. Following the sale, the insider owned 9,519 shares of the company’s stock, valued at approximately $115,941.42. This represents a 55.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 10.73% of the company’s stock.

Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.

Featured Stories

Receive News & Ratings for Adherex Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adherex Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.